It is being reported that Genentech, which makes two drugs that are proving effective for treating blindness in seniors, is only pushing the more expensive of the two.

In my opinion, this is one of the problems with our health care system.

Kevin Freking of the Associated Press writes that the difference in cost between the two drugs is almost $2,000. per dose.

Of course, Genentech states the cheaper drug, Avastin, is a cancer treating drug and was not originally intended for the treatment of macular degeneration.

So- after the very good news that Avastin is proving effective for senior blindness, Genentech is not seeking federal approval for the less expensive drug.

Why?

Could greed have something to do with it?

Blindness runs in my family. My great-grandmother went blind, as did my grandmother. It is not comforting to see this kind of coporate reaction to a serious problem that has plagued my family for several generations.

Frankly, if one blind older person can be spared the worry of not being able to see to cook, and not being burned, maybe that’s priceless.

What do you think? Write in and let us, as well as Genentech, know.
Read more Study Outcome Won’t Sway Company on Eye Drug

Popularity: 1% [?]

Be Sociable, Share!

•